Preclinical research, when related to molecular biology data analysis, mostly includes statistical analysis to identify significantly differentiated molecules in the phenotypes under study. This process leads to a high false positive rate and when corrections for multiple testing are performed, most of the time no significant changes are found. Furthermore, the process of finding molecules to target is time consuming and expensive. Many experts are utilizing a multitude of commercial and open source tools to achieve this task.
With InSyBio’s patent-pending network analysis technology, we are able to identify molecules differentiated at the network level and be more confident that these markers are more likely to be linked with the cause of the disease instead of its outcome or symptoms. Moreover, InSyBio can significantly reduce the time and money needed for a single biomarker discovery analysis by integrating the whole process in our main product, InSyBio Suite, which minimizes the effort needed by bioinformatics experts for the analysis.
InSyBio’s services for Pharmaceutical companies can save time and money by: